• Home
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Journal PharmaceuticalIntelligence.com
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2022 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • SOP Web STAT
  • Blockchain Transactions Network Ecosystem
  • Contact Us
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series
  • Press Releases
  • Intangibles CIM

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Feeds:
Posts
Comments

Deals, Funding and Partnerships

  • LPBI Group – Deals, Funding and Partnerships – Early Stage Start Ups in need for funding: Biologics, Small Molecules and Medical Devices

  • http://pharmaceuticalintelligence.com/joint-ventures/

HQS – Boston, MA

Funding, Deals & Partnerships

  • Seven Types of Investment in Thirty Business Opportunities with GDE Enterprises
  • Corporate Clients for our Services
  • Funding Cardiovascular Medical Devices Development
  • Funding Biologics Development
  • Funding Diagnostics
  • Funding Partnerships in IP Development
  • M&A and Exit
  • Targeting Penetration in New Markets for High Technology Products
  • Modeling the Management of Intellectual Property Royalties

OUR CURRENT PLAN FOR FUNDING LPBI Group’s BUSINESS #2:

Deals, Funding and Partnerships

  • 20 early stage start ups – Under discussion with two of our Investment Houses (NYC, Paris)
  • NEW – Funding an Incubator, Tech-Innovate, Presentation by CEO, Mike Eisen, NDAs, continue negotiations

NEWS

  • 9/28/2015 @9AM Skype with Haim Kravitz of AngelNet – Follow up meeting on 10/7
  • Skype with P. Corne need be rescheduled
  • 10/2 Skype with Antoine Loth, requested information on Excel File of Companies – Clients
  • BY INVITATION ONLY — October 13th in Boston – Aviva accepted the invitation attend

the Visionary’s complimentary Investor Roundtables & ‘Meet Your Match’ Welcoming Receptions on Thursday September 24th in New York City (confirmed details below), and then October 13th in Boston, October 22nd in Los Angeles, and October 28th in San Francisco.

From: Janice Dru <janice@inkwhy.com>

Date: September 22, 2015 at 7:28:49 AM EDT

To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>

Subject: Exclusive Invitation to Visionary by Janice Dru

Dear Aviva,

As a member of the Visionary network founded by Princeton alumni, I have the privilege to invite you to Visionary’s complimentary Investor Roundtables & ‘Meet Your Match’ Welcoming Receptions on Thursday September 24th in New York City (confirmed details below), and then October 13th in Boston, October 22nd in Los Angeles, and October 28th in San Francisco.

The purpose of each event is to coordinate introductions among leading entrepreneurs, investors and executives at the forefront of their industry (Consumer, Entertainment, Health, Real Estate, Renewable Energy, Technology) who are seeking to connect with each other, exchange knowledge via Featured Presentations, and detail how to opt-in to Visionary’s matching process.

RSVP via rsvp@Visionary.is to confirm your desire to attend, specifying the name/date of the event. Visionary will respond with full venue, agenda, and matching process details. If now is not your best timing to take part, or if you wish to refer other exceptional individuals into Visionary as part of the Referral Exchange, please indicate that via the RSVP.

All the best to meet your matches in Visionary!

Regards,

Janice

 

**************************************

About: Visionary (www.Visionary.is) is a by-invitation-only business match making network arranging trusted meetings, supported to success, among leading entrepreneurs, investors, executives and subject matter experts (an exclusive, curated “eHarmony for business”).

– No fee to review/access meeting requests – Who are you seeking? www.visionaryaccess.net/survey

– On-demand access to others in the network via a tiered membership and referral exchange

– Founders’ Circle opportunity to take a stake and grow the network

 

Event: Visionary Investor Roundtables & ‘Meet Your Match’ Welcoming Reception – complimentary food/drinks will be served

Date:  September 24th New York City (confirmed details below), October 13th in Boston, October 22nd in Los Angeles, and October 28th in San Francisco

Time: 3:30 p.m. to 5:30 p.m. local time Accredited Investor Only Roundtables, followed by 5:30 p.m. to 8:00 p.m. local time ‘Meet Your Match’ Welcoming Reception

Location and Agenda: Venue address and event agenda available upon RSVP (rsvp@Visionary.is)

Industries/Stages Represented by attending Visionary Members:  Consumer, Entertainment, Health, Real Estate, Renewable Energy, Technology // Early, Growth, Public Company, Funds

 

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to print (Opens in new window)
  • Click to email a link to a friend (Opens in new window)

Like this:

Like Loading...

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 9,459 other subscribers
  • Recent Posts

    • Creating a Twitter Space for @pharma_BI for Live Broadcasts March 14, 2023
    • The Vibrant Philly Biotech Scene: Recent Happenings & Deals March 11, 2023
    • Peak oxygen uptake (VO2peak) quantified fitness: Lifelong and late-onset athletes had higher VO2peak than non-athletes March 7, 2023
    • Merck’s sotatercept overachieves, PCSK9 inhibitor passes phase 2 March 6, 2023
    • Bacterial multidrug resistance problem solved by a broad-spectrum synthetic antibiotic March 1, 2023
    • Genetic variation causes human lupus, systemic lupus erythematosus (SLE) February 23, 2023
    • Mimicking vaginal cells and microbiome interactions on chip microfluidic culture February 14, 2023
    • Press Release for Five Bilingual BioMed e-Series in English and in Spanish January 29, 2023
    • 2022 FDA Drug Approval List, 2022 Biological Approvals and Approved Cellular and Gene Therapy Products January 17, 2023
    • Verily announced other organizational changes, 1/13/2023 January 16, 2023
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 Amandeep Kaur
    • 1 Aashir Awan, Phd
    • 1 Abhisar Anand
    • 1 Adina Hazan
    • 1 Alan F. Kaul, PharmD., MS, MBA, FCCP
    • 1 alexcrystal6
    • 1 anamikasarkar
    • 1 apreconasia
    • 1 aviralvatsa
    • 1 David Orchard-Webb, PhD
    • 1 danutdaagmailcom
    • 1 Demet Sag, Ph.D., CRA, GCP
    • 1 Dror Nir
    • 1 dsmolyar
    • 1 Ethan Coomber
    • 1 evelinacohn
    • 1 Gail S Thornton
    • 1 Irina Robu
    • 1 jayzmit48
    • 1 jdpmd
    • 1 jshertok
    • 1 kellyperlman
    • 1 Ed Kislauskis
    • 1 larryhbern
    • 1 Madison Davis
    • 1 marzankhan
    • 1 megbaker58
    • 1 ofermar2020
    • 1 Dr. Pati
    • 1 pkandala
    • 1 ritusaxena
    • 1 Rick Mandahl
    • 1 sjwilliamspa
    • 1 Srinivas Sriram
    • 1 stuartlpbi
    • 1 Dr. Sudipta Saha
    • 1 tildabarliya
    • 1 vaishnavee24
    • 1 zraviv06
    • 1 zs22

Powered by WordPress.com.

WPThemes.


%d bloggers like this: